Clinical trial · Observational
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (LUNGEVITY STUDY)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment. Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study. They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic NSCLC | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Metastatic Small Cell Lung Cancer | Lung Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hospital Anxiety and Depression scale (HAD) | Behavioral | — | UNRESOLVED |
| Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13) | Behavioral | — | UNRESOLVED |
| Questionnaire Aix-Marseille-Université (AMU) | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Long-Terms Responders in metastatic Lung Cancer
- description
- Long-term responders defined as patients alive for three years after diagnosis of metastatic Lung cancer (NSCLC and SCLC) and not receiving cytotoxic chemotherapy at the time of inclusion.
- interventionNames
- Behavioral: Hospital Anxiety and Depression scale (HAD)
- Behavioral: Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)
- Behavioral: Questionnaire Aix-Marseille-Université (AMU)
Primary outcomes (7)
- measure
- Baseline Clinical Characteristics
- timeFrame
- At Baseline visit, on a maximum period of 12 months.
- description
- Metastatic Lung Cancer Long-Terms Responders clinical characteristics: baseline patient demographics, clinical and pathological characteristics (e.g. age, medical history, comorbidities, past history of cancer, smoking status, NSCLC or SCLC characteristics)
- measure
- Aix-Marseille-University (AMU) questionnaire
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient over 18 years old * Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance). * Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance Exclusion Criteria: * Difficulties for understanding French * Patients undergoing treatment with cytotoxic chemotherapy * Patients under legal guardianship, under curatorship or tutorship * Insufficient cognitive capacity to answer questions * Inability to obtain data collection (lost to follow-up, patient's refusal for data collection) * Patients refusing the collection of their data (an information sheet will be provided)
References
Publications (0)
Data not yet available